| P2093 | author name string | Mariana Verdelho Machado | |
| P2860 | cites work | Non-alcoholic fatty liver disease: what the clinician needs to know | Q24563068 |
| | Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis | Q30592294 |
| | T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis | Q33857534 |
| | Liver biopsy | Q33932981 |
| | Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. | Q34222246 |
| | A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? | Q35001617 |
| | Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B | Q35555702 |
| | The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification | Q35664425 |
| | Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 |
| | The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease. | Q36717062 |
| | Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD. | Q37206782 |
| | Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. | Q37257281 |
| | Insulin resistance and steatosis in chronic hepatitis C. | Q37452762 |
| | Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study | Q37657417 |
| | Diagnosis and management of alcoholic liver disease | Q37811070 |
| | Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. | Q37886042 |
| | Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. | Q38062786 |
| | Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality | Q38776206 |
| | Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World | Q38803839 |
| | Non-invasive diagnosis of hepatic steatosis. | Q38991269 |
| | Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. | Q39745120 |
| | The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population | Q39837126 |
| | Impact of Nonalcoholic Fatty Liver Disease on Myocardial Perfusion in Nondiabetic Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction | Q40387500 |
| | The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response | Q40505261 |
| | Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 |
| | How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound | Q44751613 |
| | Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without | Q44983054 |
| | Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study | Q45069240 |
| | Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? | Q45206614 |
| | Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. | Q51161258 |
| | Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. | Q51171810 |
| | Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. | Q51714520 |
| | Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease. | Q55045481 |
| | Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. | Q64936845 |
| | Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography | Q86755842 |
| | Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression | Q87044465 |
| | Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy | Q87188693 |
| P433 | issue | 4 | |
| P921 | main subject | steatosis | Q1365091 |
| | chronic liver disease | Q5113984 |
| | noninvasive method | Q111303348 |
| P304 | page(s) | 157-160 | |
| P577 | publication date | 2017-07-04 | |
| P1433 | published in | GE: Portuguese Journal of Gastroenterology | Q50817053 |
| P1476 | title | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? | |
| P478 | volume | 24 | |